36 results about "Haemoglobin Suresnes" patented technology

An electrochemically active device is provided for collecting and retaining a blood sample with at least a two-electrode member connected to conductive tracks. A receptor with an integral receptor-membrane arranged on the two-electrode member, to receive non-electrochemically active heamoglobin bioanalyte and its complexes from red blood cells (RBC) of said blood sample, through a lysing agent and convert the non-electrochemically active heamoglobin bioanalyte and its complexes, into an electrochemically active bioanalyte and its electrochemically active complexes. The present invention also provides a point-of-care biosensor incorporated with the device of the present invention and method of measuring for the detection and quantitative measurement of concentrations of haemoglobin (Hb), glycated haemoglobin (GHb), methaemoglobin (MetHb) and myoglobin, in reduced volumes of blood samples, by determining redox current values in the reduced volumes of blood samples.

The invention provides an assay method for determining a level of haptoglobin in a sample comprising the steps of: (i) mixing haemoglobin with the sample to be assayed so as to form a haptoglobin-haemoglobin complex with haptoglobin present in the sample; (ii) contacting the product of step (i) with reagents for generating hydrogen peroxide and one or more chromogens which undergo a spectroscopically detectable change when peroxidase activity is present, in the presence of a buffer, under conditions in which hydrogen peroxide is generated from said reagents and forms a substrate for the peroxidise activity of the haptoglobin-haemoglobin complex present, and wherein the pH of the buffer is within a range which is sufficiently low that the peroxidise activity of any uncomplexed haemoglobin is substantially suppressed but sufficiently high that hydrogen peroxide generation occurs; (iii) determining the peroxidase activity of the haptoglobin-haemoglobin complex by measuring the change in an optical property of the reaction mixture; and (iv) correlating the level of peroxidise activity of the haptoglobin-haemoglobin complex with the amount of haptoglobin in the sample. A kit for use in such a method is also provided.

Disclosed is an in vitro method for assessing whether a human patient suffering from periodontitis has mild periodontitis or advanced periodontitis. The method is based on the insight to determine a selection of three bio marker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the concentrations are measured of the proteins Pyruvate Kinase (PK) and at least twoof Haemoglobin-beta (Hb-beta), Haemoglobin-delta (Hb-delta), S100 calcium-binding protein A8 (S100A8) and S100 calcium-binding protein A9 (S100A9). Based on the concentrations as measured, a value reflecting the joint concentrations for said proteins is determined. The value is compared with a threshold value reflecting in the same manner the joint concentrations associated with advanced periodontitis. The comparison allows assessing whether the testing value is indicative of the presence of advanced periodontitis or of mild periodontitis in the patient. Thereby, typically, a testing value reflecting a joint concentration below the joint concentration reflected by the threshold value is indicative for mild periodontitis in the patient, and a testing value reflecting a joint concentration at or above the joint concentration reflected by the threshold value, is indicative for advanced periodontitis in the patient.

The present invention relates to a method for determining the amount of glycated haemoglobin (HbA1c), in which -if required -the erythrocytes in a sample are haemolysed, the haemoglobin that is then released -if required -is contacted with a proteolytic agent and the glycated haemoglobin degradation products obtained in this way or otherwise are quantified. In order to provide such a process and reagents employable therein that has / have the property of sufficient stability of the chemical compounds that are essential to the reaction, the provision of the requisite proteolytic agent in the form of an inactivated protease is proposed, which is then only reactivated in situ. In particular embodiments of the invention, for the stabilization of the haemoglobin which is unfolded at a very low pH in the range from 1 to 3, at least one suitable stabilizer should be present in the haemolysis solution, and, in the embodiments of the invention in which a leuco dye is used in connection with the determination of the amount of HbA1c, it is proposed in accordance with the invention that the latter be stabilized with particular phosphine compounds and / or thio compounds.

The invention relates to a method for validating a biometrical acquisition, mainly the acquisition of a body imprint of a body area such as fingerprints or a face imprint, wherein the method involves together with the biometric acquisition: lighting the body area using at least one radiation having at least two respective different wavelengths between approximately 500 nm and 1150 nm; taking at least two reflectometry measurements concerning said and at least two wavelengths for measuring the reflection index of the tissues for these wavelengths; calculating the ratio for the two measured indices; and comparing the ratio with a range of reference values characterising a haemoglobin-containing living tissue in terms of proportions of oxygenated and non-oxygenated forms characteristic of the living state for the wavelengths in question; if the ratio is included in said range, the body area is considered as living and the biometrical acquisition is validated; and conversely, if the body area is considered as not living, the biometrical acquisition cannot be validated.

The present invention relates to isolated haemoglobin from worms belonging to the Nereididae family and its use in cell culture medium, in preservation solutions and as artificial oxygen carrier for transfusion.

A method for determining a prognosis for benefit for a cancer patient receiving immunotherapy treatment involving (a) measuring a level of haematocrit and haemoglobin in a sample from the cancer patient, and (b) comparing the level of haematocrit in the sample to a reference level of platelets and comparing the level of haemoglobin in the sample to a reference level of haemoglobin, wherein a lower level of haematocrit and higher level of haemoglobin in the sample correlates with increased benefit to the patient.

The present invention relates to an iron carbohydrate complex for use in a method of increasing the blood haemoglobin concentration in a pregnant non-human mammal, wherein the pregnant non-human mammal having a blood haemoglobin level of 105 g / L or less, is administered one or more doses of iron carbohydrate complex comprising an amount of elemental iron of 1800 mg or more per dose. The method relates to the further effects of decreasing the rate of stillborn offsprings from a pregnant non-human mammal having a blood haemoglobin level of 105 g / L or less, increasing the blood haemoglobin concentration of offspring litters within 3 days from birth and / or weaning, or increasing the litter size in a subsequent parity of a non-human mammal having a blood haemoglobin level of 105 g / L or less.

The invention relates to the use of at least one extracellular globin, globin protomer or haemoglobin from annelids, for maintaining stem cells in the undifferentiated state.

The present invention relates to a container comprising haemoglobin fractions, wherein said container comprising at least two compartments, wherein a first compartment comprises O2Hb (oxyhaemoglobin) and a second compartment comprises MetHb (methaemoglobin), optionally wherein O2Hb is stabilized. The invention also relates to a kit for determining the reliability of a CO-oximetry device, wherein said kit comprises said container and to a method for determining the reliability of a CO-oximetry device using said container.

A method for determining the amount of glycated hemoglobin (HbA1c), in which—if required—the erythrocytes in a sample are hemolyzed, the haemoglobin that is then released—if required—is contacted with a proteolytic agent and the glycated hemoglobin degradation products obtained in this way or otherwise are quantified is disclosed. In order to provide such a process and reagents employable therein that has / have the property of sufficient stability of the chemical compounds that are essential to the reaction, the provision of the requisite proteolytic agent in the form of an inactivated protease is proposed, which is then only reactivated in situ. For the stabilization of the hemoglobin, which is unfolded at a very low pH in the range from 1 to 3, at least one suitable stabilizer should be present in the hemolysis solution, and, where a leuco dye is used in connection with the determination of the amount of HbA1c, it is proposed that the latter be stabilized with particular phosphine compounds and / or thio compounds.

The present invention relates to a container comprising haemoglobin fractions, wherein said container comprising at least two compartments, wherein a first compartment comprises O2Hb (oxyhaemoglobin) and a second compartment comprises MetHb (methaemoglobin), optionally wherein O2Hb is stabilized. The invention also relates to a kit for determining the reliability of a CO-oximetry device, wherein said kit comprises said container and to a method for determining the reliability of a CO-oximetry device using said container.

Disclosed is an in vitro method for assessing the presence of gingivitis in a human subject. The method is based on the insight to determine a selection of three biomarker proteins. Accordingly, in asaliva sample of the subject the concentrations are measured of the proteins Hepatocyte growth factor (HGF) and Interleukin-1 beta (IL-1beta), and at least one of C reactive protein (CRP) and Haemoglobin. Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with the absence of gingivitis or periodontitis. The comparison allows to assessing whether the testing value is indicative of the presence of gingivitis in said subject. Thereby, typically, a testing value reflecting a joint concentration above the joint concentration reflected by the threshold, is indicative of the presence of gingivitis.